Company news
BioRestorative Therapies, Inc. news in 2022
BioRestorative Therapies, Inc.'s news releases, calls and decks from 2022, newest first.
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
December 5, 2022
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
December 4, 2022
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 29, 2022
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 21, 2022
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 12, 2022
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 28, 2022
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 17, 2022
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 3, 2022
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
March 9, 2022
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
February 15, 2022
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
February 6, 2022
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
February 1, 2022
BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
January 10, 2022
BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells
January 3, 2022
Decks in 2022
- Investor Presentation (October 2022)
Investor deck · 23 slides · October 2022
- Investor Presentation (September 2022)
Investor deck · 26 slides · Sep 13, 2022
- Investor Presentation (September 2022)
Investor deck · 26 slides · September 2022
- Investor Presentation (June 2022)
Investor deck · 25 slides · June 2022